Effect of steroids on CSF matrix metalloproteinases in multiple sclerosis: relation to blood-brain barrier injury.
about
Kallikreins are associated with secondary progressive multiple sclerosis and promote neurodegenerationFriends or Foes: Matrix Metalloproteinases and Their Multifaceted Roles in Neurodegenerative DiseasesSerum uric acid levels in multiple sclerosis patients correlate with activity of disease and blood-brain barrier dysfunctionThe blood-brain-barrier in multiple sclerosis: functional roles and therapeutic targetingSystemic expression of matrix metalloproteinase-9 in patients with cerebral arteriovenous malformations.Diffusely abnormal white matter in multiple sclerosis: further histologic studies provide evidence for a primary lipid abnormality with neurodegeneration.Endoneurial remodeling by TNFalph- and TNFalpha-releasing proteases. A spatial and temporal co-localization study in painful neuropathy.Recent developments in drug therapy for multiple sclerosis.Maternal hypoxia increases the activity of MMPs and decreases the expression of TIMPs in the brain of neonatal ratsManagement of acute exacerbations in multiple sclerosis.Correlation Between Cannabidiol-Induced Reduction of Infarct Volume and Inflammatory Factors Expression in Ischemic Stroke Model.The role of TNFalpha and lymphotoxin in demyelinating disease.The innate immune response affects the development of the autoimmune response in Theiler's virus-induced demyelinating disease.Antiinflammatory activity of melatonin in central nervous systemCerebrospinal fluid matrix metalloproteinases are elevated in cerebral adrenoleukodystrophy and correlate with MRI severity and neurologic dysfunction.Metzincin proteases and their inhibitors: foes or friends in nervous system physiology?Cytokines in multiple sclerosis: methodological aspects and pathogenic implications.Matrix metalloproteinases and neuroinflammation in multiple sclerosis.Pharmacological methods to overcome IFN-beta antibody formation in the treatment of multiple sclerosis.Dexamethasone inhibits brain apoptosis in mice with eosinophilic meningitis caused by Angiostrongylus cantonensis infection.Kaempferol acts through mitogen-activated protein kinases and protein kinase B/AKT to elicit protection in a model of neuroinflammation in BV2 microglial cellsInterferon-beta-1a in relapsing-remitting multiple sclerosis: effect on hypointense lesion volume on T1 weighted imagesDisruption in the Blood-Brain Barrier: The Missing Link between Brain and Body Inflammation in Bipolar Disorder?Differential expression of extracellular matrix remodeling genes in a murine model of bleomycin-induced pulmonary fibrosis.Kallikrein 6 regulates early CNS demyelination in a viral model of multiple sclerosis.Serum matrix metalloproteinase-3 levels correlate with disease activity in relapsing-remitting multiple sclerosis.The potential use of MMP inhibitors to treat CNS diseases.Cerebrospinal fluid matrix metalloproteinase-9 increases during treatment of recurrent malignant gliomasCleavage of myelin associated glycoprotein by matrix metalloproteinases.Brain endothelial dysfunction in cerebral adrenoleukodystrophy.TWEAK/Fn14 pathway modulates properties of a human microvascular endothelial cell model of blood brain barrier.Glucocorticoids in multiple sclerosis and experimental autoimmune encephalomyelitis.Corticosteroids for multiple sclerosis: I. Application for treating exacerbations.Matrix metalloproteinase-2 facilitates wound healing events that promote functional recovery after spinal cord injury.Matrix metalloproteinases limit functional recovery after spinal cord injury by modulation of early vascular events.Corticosteroids in the treatment of multiple sclerosis.Melatonin plus exercise-based neurorehabilitative therapy for spinal cord injury.Neurological diseases in relation to the blood-brain barrier.The role of microglia and matrix metalloproteinases involvement in neuroinflammation and gliomasTranscriptional Regulation of Brain-Derived Neurotrophic Factor (BDNF) by Methyl CpG Binding Protein 2 (MeCP2): a Novel Mechanism for Re-Myelination and/or Myelin Repair Involved in the Treatment of Multiple Sclerosis (MS).
P2860
Q24643613-850D8A21-30F0-4D1F-AC98-28BCAB5D2146Q26779933-3BD0C84D-34E2-412F-8BE9-1ACDCC3CCC69Q28216262-F51D0091-FD8B-413E-875B-D05EFC14446DQ28299076-B93869A0-B8E7-4632-85AA-9C3279A0CCC2Q30449965-C96F6B51-09F2-4DDB-8C4B-229ADE87A02EQ30581773-FA20FF5C-89F5-4D61-8DC7-A45090B4E57AQ30830869-EC30A7BD-2D92-4502-9F47-7B4EC7F581E4Q33639891-3971E09D-DD59-4C74-88B9-22F5D2F65D5DQ33642536-80D84DB4-FCF5-428E-A12A-C3C8B26FD04CQ33670934-10B49C9D-36D9-4C06-8E36-58415F0D4CC3Q33716712-6DBBD164-0055-4A76-959C-6E06622D57BBQ33782397-C2FD9240-6FBF-4F23-93B3-88A9BE03D03EQ33877666-D7D0DD5B-8ED6-41E9-A35F-D339A0824926Q34402174-9238E65E-DE00-42A2-A668-986BFBA273B5Q34491461-6E5B9544-1D3C-4C91-85F3-02C6CD00EE1CQ34768858-8F06DCBF-9381-4833-B087-F40F32BD7E75Q34924266-E9945EA9-F377-411A-9F47-E6A5EF903E1CQ35017633-F94FDCAE-2E56-4663-80FC-15BD3A5C0EA6Q35164752-C8A1047D-A6F0-4256-82D7-7BF4CE2B6F8BQ35246572-F7D49CFD-87FC-42A1-9527-97A034CC91D9Q35376097-8D9B6F2C-8EF5-404E-8EF0-820F8C4FC39CQ35454159-BEAB62FB-3B0A-46A9-A6B0-B875242F85BBQ35649716-AC899D5B-91AA-4FDC-B27E-0F1CA9E752F6Q35765029-D6304695-22B0-47B0-98E7-051F21FA7EB4Q35987823-5384DDE1-BDCC-4E6D-A023-2E501CC95B11Q36142537-10C41E74-6FA2-4F80-804D-DDA56E4FCFB0Q36181275-E3AEEFE8-AFA9-4962-9DA2-AEA56C16DFE3Q36489234-A54F008F-8D85-4957-A14E-590F5809663FQ36513220-1EA25287-9774-42B1-8295-8D8621E222A6Q36515946-D22BE26C-8BE5-4D92-9973-03A7FCFBA088Q36604118-40FE7E43-1C9E-4E13-A004-D8BC8EF8FDFDQ36673022-BBC38BB2-5965-4B5D-B1C2-70713BFC5D22Q36963166-FF759863-E47D-447C-BD7F-274D2EA18D54Q37138010-83562B2D-1770-4C84-B81D-B104B277982FQ37471962-DE7B19B9-E429-4EA0-83A1-8DCF6260862DQ37536089-02CBBB08-178C-4764-816A-290823223152Q37772219-10601C53-2EFF-407E-86B6-53914483BE0AQ37976564-69590AF1-19BC-4F04-985C-2B513B132CF9Q38136195-8F767AD1-FABD-4B1E-AF39-AB2B7307E641Q38314584-A9F3B907-9A52-4E68-B624-DFFB7ECED2D2
P2860
Effect of steroids on CSF matrix metalloproteinases in multiple sclerosis: relation to blood-brain barrier injury.
description
1996 nî lūn-bûn
@nan
1996年の論文
@ja
1996年学术文章
@wuu
1996年学术文章
@zh-cn
1996年学术文章
@zh-hans
1996年学术文章
@zh-my
1996年学术文章
@zh-sg
1996年學術文章
@yue
1996年學術文章
@zh
1996年學術文章
@zh-hant
name
Effect of steroids on CSF matr ...... to blood-brain barrier injury.
@en
Effect of steroids on CSF matr ...... to blood-brain barrier injury.
@nl
type
label
Effect of steroids on CSF matr ...... to blood-brain barrier injury.
@en
Effect of steroids on CSF matr ...... to blood-brain barrier injury.
@nl
prefLabel
Effect of steroids on CSF matr ...... to blood-brain barrier injury.
@en
Effect of steroids on CSF matr ...... to blood-brain barrier injury.
@nl
P2093
P356
P1433
P1476
Effect of steroids on CSF matr ...... to blood-brain barrier injury.
@en
P2093
Correa N Jr
Dencoff JE
Rosenberg GA
P304
P356
10.1212/WNL.46.6.1626
P407
P577
1996-06-01T00:00:00Z